Angle PLC Supporting characterisation of CTCs in HNSCC
2023年10月25日 - 3:00PM
RNSニュース (英語)
TIDMAGL
Angle PLC
25 October 2023
For immediate release 25 October 2023
ANGLE plc ("the Company")
RESEARCH DEMONSTRATES POTENTIAL OF THE PARSORTIX SYSTEM TO
SUPPORT POWERFUL CHARACTERISATION OF CTCS IN HEAD AND NECK
CANCER
41 key biomarkers including the immune checkpoint proteins
PD-L1, CTLA4 and CD39 successfully evaluated
Providing key information which could support the development of
personalised treatment strategies in HNSCC
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company with innovative circulating tumour cell (CTC) diagnostic
solutions for use in research, drug development and clinical
oncology, is pleased to announce the publication of a study using
the Parsortix system that sheds new light on the phenotypic
characteristics of CTCs in Head and Neck Squamous Cell Carcinoma
(HNSCC).
The study, conducted by researchers at the University of
Birmingham, UK, demonstrates the feasibility of using mass
cytometry, a powerful technique widely used for single cell
analysis, for the comprehensive characterisation of CTCs captured
by the Parsortix system in HNSCC patients. This advanced technology
enables simultaneous analysis of multiple proteins on and within
individual CTCs, providing a deep understanding of their phenotypic
status and diversity. As a marker-independent method for CTC
harvesting, the Parsortix system was able to isolate a diversity of
CTCs revealing a correlation between epithelial to mesenchymal
transition and immune checkpoint protein expression.
HNSCC is an aggressive, genetically complex, and difficult to
treat group of cancers with limited options for early detection and
monitoring. Head and Neck cancers are a significant global health
concern with 900,000 new cases each year at an estimated cost to
the global economy of more than US$40 billion per annum. The
findings of this study provide new insight into the molecular
heterogeneity of HNSCC and offers the potential to enable
development of more precise and personalised treatment strategies
for patients and real-time monitoring of treatment response.
Furthermore, the protocol established in this publication holds
promise as a tool for the use of proteomic data, obtained from
Parsortix harvested CTCs, to be used for novel biomarker
development and the potential for identification of patients who
may be eligible for immune checkpoint inhibitor therapy.
The study is published as a peer-reviewed journal article in the
British Journal of Cancer and is available online at
https://angleplc.com/publications/ .
Principal Investigator, Dr Karl Payne, NIHR Clinical Lecturer in
Oral & Maxillofacial Surgery from the Institute of Cancer and
Genomic Sciences, University of Birmingham, UK, commented:
"To our knowledge, our work represents the first use of cell
suspension mass cytometry to characterise CTCs. With this protocol,
phenotype and activation status of critical intracellular cell
signalling proteins can be measured in CTCs and peripheral blood
immune cells. By allowing high-dimensional single-cell CTC data to
be obtained from patients recruited across multiple research sites,
we believe our method will accelerate clinical study recruitment
and enable robust analysis of CTCs in rare cancers."
ANGLE Chief Scientific Officer, Karen Miller, commented:
"We are pleased to share this peer-reviewed publication by the
University of Birmingham demonstrating the high-throughput and high
sensitivity of mass cytometry for downstream multiplexed analysis
of both surface and intracellular proteins on and in CTCs. In this
study, the heterogeneity of CTC sub-groups and their relationship
to targetable markers, in particular the druggable immune
checkpoints, is notable. The Parsortix system allows for the
unbiased isolation and harvest of CTCs and as such, can enable the
evaluation of phenotypically diverse CTCs in a patient's blood.
This could lead to future improvements in clinical decision
making."
For further information:
ANGLE plc
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director +44 (0) 1483 343434
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Thomas Bective, Shaam Vora +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
For Research Use Only. Not for use in diagnostic procedures.
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative
circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology using a simple
blood sample. ANGLE's FDA cleared and patent protected circulating
tumour cell (CTC) harvesting technology known as the Parsortix(R)
PC1 System enables complete downstream analysis of the sample
including whole cell imaging and proteomic analysis and full
genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic
products and clinical services. Diagnostic products include the
Parsortix(R) system and associated consumables. The clinical
services business is offered through ANGLE's GCP-compliant
laboratories in the UK and the United States. Services include
custom made assay development and clinical trial testing for
pharma.
Over 80 peer-reviewed publications have demonstrated the
performance of the Parsortix system. For more information, visit
www.angleplc.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFEFFWLEDSESS
(END) Dow Jones Newswires
October 25, 2023 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
過去 株価チャート
から 5 2024 まで 6 2024
Angle (LSE:AGL)
過去 株価チャート
から 6 2023 まで 6 2024